Observational studyBMC gastroenterology2026
Systematic immunological evaluation in adult patients with inflammatory bowel disease.
Observational study in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammatory bowel disease (IBD) has been frequently reported in patients with primary immunodeficiency; however, the frequency and pattern of immunological abnormalities among adult patients with established IBD remain insufficiently characterized. We aimed to systematically evaluate immunological parameters in adult patients with established IBD. Additionally, we sought to identify clinical factors associated with laboratory-defined immunological deviations.
methodsIn this retrospective observational cohort study, we analyzed 108 adults with Crohn's disease or ulcerative colitis who underwent structured immunological evaluation as part of routine clinical care between 2011 and 2015 (a period of standardized screening). We excluded patients with major causes of secondary immunodeficiency (e.g., advanced renal failure, HIV infection, severe malnutrition). However, we recorded exposure to medications that could potentially cause secondary immunosuppression. The predefined laboratory panel included serum immunoglobulins, vaccine antibody responses, isohemagglutinin titers (not assessed in blood group AB), peripheral lymphocyte subsets (reported as percentages), and neutrophil phagocytic function, interpreted using standardized reference ranges. Immunological findings were categorized according to the IUIS 2025 phenotypic framework. Multivariable logistic regression was performed to assess factors associated with laboratory-defined immunological deviations.
resultsClinically significant immunological disorders were identified in 12 patients (11.1%), and laboratory-defined (defined as combined defects across immune compartments) immunological deviations in 60 patients (55.6%). Reduced CD19⁺ B-cell percentages were observed in 45 patients (42.1%) and decreased NK cell percentages in 17 patients (15.9%). In multivariable analysis, increasing age (OR 1.064 per year; 95% CI 1.029-1.100; p < 0.001) and male sex (OR 3.61; 95% CI 1.32-9.87; p = 0.012) were independently associated with laboratory-defined immunological deviations; medication exposure showed a borderline association (OR 2.78; 95% CI 0.99-7.76; p = 0.052).
conclusionsIn this adult IBD cohort evaluated using a structured laboratory framework, measurable immune alterations were common, although most did not meet criteria for clinically significant immunological disorders. These findings highlight immune heterogeneity in adult IBD and support further prospective studies with longitudinal outcomes to clarify the clinical implications and to define which patient subgroups may benefit from targeted immunological assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.